(Q33385389)

English

Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

M C Levesque

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

1 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Clinical and Experimental Immunology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

157

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

198-208

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

CD20+ T-Cell Lymphoma:Neoplastic Transformation of a Normal T-Cell Subset

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2009.03979.X

21 January 2018

Complement activation determines the therapeutic activity of rituximab in vivo.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2009.03979.X

21 January 2018

Systematic review: agranulocytosis induced by nonchemotherapy drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2009.03979.X

21 January 2018

Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2009.03979.X

21 January 2018

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2009.03979.X

21 January 2018

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2009.03979.X

21 January 2018

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2009.03979.X

21 January 2018

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2009.03979.X

21 January 2018

Innate immunity and human B cell clonal expansion: effects on the recirculating B2 subpopulation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2009.03979.X

21 January 2018

Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2009.03979.X

21 January 2018

B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells

2 references

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2009.03979.X

21 January 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Emerging therapeutics for rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Rituximab in relapsing Graves' disease, a phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

New approaches of B-cell-directed therapy: beyond rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

The effect of anti-CD40 ligand in immune thrombocytopenic purpura

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

B cell-directed therapies for autoimmune disease and correlates of disease response and relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Platelet pro-aggregatory effects of CD40L monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

A single cycle of rituximab for the treatment of severe pemphigus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Rituximab therapy in malignant lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Serum sickness following treatment with rituximab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

To switch or not to switch--the opposing roles of TACI in terminal B cell differentiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

B-cell-targeted therapy for systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

B cells move to centre stage: novel opportunities for autoimmune disease treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Rituximab in the treatment of antisynthetase syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

The pathogenesis of immune thrombocytopaenic purpura

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

B-cell targeting in rheumatoid arthritis and other autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

B cell immunobiology in disease: evolving concepts from the clinic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Rituximab as therapy for refractory polymyositis and dermatomyositis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

An APRIL to remember: novel TNF ligands as therapeutic targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

The therapeutic potential of anti-CD20 "what do B-cells do?".

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

The role of BAFF in immune function and implications for autoimmunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Antibody therapy for chronic lymphocytic leukemia: a promising new modality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

BAFF: a fundamental survival factor for B cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Immune thrombocytopenic purpura

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

CD20: a regulator of cell-cycle progression of B lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730845

31 October 2018

New prospects for autoimmune disease therapy: B cells on deathwatch

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD20 blockers eye crowded rheumatology market

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complement activation plays a key role in the side-effects of rituximab treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituxan warning

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot trial of rituximab in the treatment of patients with dermatomyositis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of psoriasis after B cell depletion with rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibodies, immunogenicity, and associated infusion reactions

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/19604259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2249.2009.03979.X

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

release_jcihxafrjfbnthgq5xvvatp6sm

1 reference

https://api.fatcat.wiki/v0/release/jcihxafrjfbnthgq5xvvatp6sm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33385389&oldid=1836245366"